Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases

JCO Precis Oncol. 2019:3:PO.19.00021. doi: 10.1200/PO.19.00021. Epub 2019 Jun 3.

Authors

Robin Guo¹, Mark Schreyer¹, Jason C Chang¹, S Michael Rothenberg², Dahlia Henry², Paolo Cotzia³, Mark G Kris^{1

4}, Natasha Rekhtman¹, Robert J Young¹, David M Hyman^{1

4}, Alexander Drilon^{1

4}

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY.
² Loxo Oncology, Stamford, CT.
³ New York University Langone Medical Center, New York, NY.
⁴ Weill Cornell Medical College, New York, NY.

No abstract available

Grants and funding